X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs IPCA LABS - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB IPCA LABS DR. REDDYS LAB/
IPCA LABS
 
P/E (TTM) x 42.0 36.4 115.5% View Chart
P/BV x 3.2 3.5 93.1% View Chart
Dividend Yield % 0.8 0.1 564.6%  

Financials

 DR. REDDYS LAB   IPCA LABS
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
IPCA LABS
Mar-17
DR. REDDYS LAB/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3,397643 528.3%   
Low Rs2,560503 509.1%   
Sales per share (Unadj.) Rs856.5254.4 336.7%  
Earnings per share (Unadj.) Rs78.016.1 485.1%  
Cash flow per share (Unadj.) Rs139.929.8 469.9%  
Dividends per share (Unadj.) Rs20.001.00 2,000.0%  
Dividend yield (eoy) %0.70.2 384.7%  
Book value per share (Unadj.) Rs739.8194.6 380.3%  
Shares outstanding (eoy) m165.74126.20 131.3%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.52.3 154.4%   
Avg P/E ratio x38.235.7 107.2%  
P/CF ratio (eoy) x21.319.2 110.6%  
Price / Book Value ratio x4.02.9 136.7%  
Dividend payout %25.76.2 412.3%   
Avg Mkt Cap Rs m493,63272,300 682.8%   
No. of employees `00022.713.3 170.5%   
Total wages/salary Rs m31,0686,960 446.4%   
Avg. sales/employee Rs Th6,259.02,413.5 259.3%   
Avg. wages/employee Rs Th1,369.8523.2 261.8%   
Avg. net profit/employee Rs Th569.7152.4 373.7%   
INCOME DATA
Net Sales Rs m141,96132,106 442.2%  
Other income Rs m1,715226 759.9%   
Total revenues Rs m143,67632,332 444.4%   
Gross profit Rs m24,7224,448 555.8%  
Depreciation Rs m10,2661,730 593.6%   
Interest Rs m634241 263.3%   
Profit before tax Rs m15,5372,703 574.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,965675 439.1%   
Profit after tax Rs m12,9212,028 637.1%  
Gross profit margin %17.413.9 125.7%  
Effective tax rate %19.125.0 76.4%   
Net profit margin %9.16.3 144.1%  
BALANCE SHEET DATA
Current assets Rs m96,83717,340 558.5%   
Current liabilities Rs m84,1999,559 880.8%   
Net working cap to sales %8.924.2 36.7%  
Current ratio x1.21.8 63.4%  
Inventory Days Days73100 73.1%  
Debtors Days Days9857 171.8%  
Net fixed assets Rs m102,55220,779 493.5%   
Share capital Rs m829252 328.4%   
"Free" reserves Rs m121,79224,499 497.1%   
Net worth Rs m122,62124,553 499.4%   
Long term debt Rs m5,4493,517 154.9%   
Total assets Rs m218,16539,595 551.0%  
Interest coverage x25.512.2 208.6%   
Debt to equity ratio x00.1 31.0%  
Sales to assets ratio x0.70.8 80.2%   
Return on assets %6.25.7 108.4%  
Return on equity %10.58.3 127.6%  
Return on capital %12.910.5 123.0%  
Exports to sales %54.648.6 112.3%   
Imports to sales %9.414.2 65.7%   
Exports (fob) Rs m77,52015,617 496.4%   
Imports (cif) Rs m13,2744,571 290.4%   
Fx inflow Rs m81,67015,617 522.9%   
Fx outflow Rs m26,3555,828 452.2%   
Net fx Rs m55,3159,790 565.0%   
CASH FLOW
From Operations Rs m21,4442,764 775.8%  
From Investments Rs m-18,404-1,432 1,285.5%  
From Financial Activity Rs m-3,692-1,591 232.0%  
Net Cashflow Rs m-1,144-259 442.0%  

Share Holding

Indian Promoters % 25.5 45.9 55.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 11.4 47.4%  
FIIs % 35.3 25.3 139.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 17.4 87.9%  
Shareholders   75,885 36,892 205.7%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  MERCK LTD  ABBOTT INDIA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jun 18, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS